Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues

Human Pathology

Volumn 27, Issue 6, 1996, Pages 573-580

  Wertz, Ingrid E ^a   Deitch, Arline D ^a   Gumerlock, Paul H ^a   Gandour Edwards, Regina ^a   Chi, Sung Gil ^a   De Vere White, Ralph W ^a  

^a NONE

Author keywords

antigen unmasking; immunohistochemistry; p53; prostatic neoplasms; single strand conformational polymorphism; TP53

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL LINE; FROZEN SECTION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0029948503     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90164-1     Document Type: Article

References (55)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA 45:8, 1995
2. Carter HB, Coffey DS: The prostate: An increasing medical problem. Prostate 16:39, 1990
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453, 1991
4. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 320:1318, 1993
5. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845, 1992
6. Martin HM, Filipe ML, Morris RW, et al: p53 prognosis in gastric carcinoma. Int J Cancer 50:859, 1992
7. Berner A, Harvei S, Tretli S, et al: Prostatic carcinoma: A multivariate analysis of prognostic factors. Br J Cancer 69:924, 1994
8. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of p53 as a prognostic indicator of prostate cancer. HUM PATHOL 26:106, 1995
9. Voeller HJ, Sugars LY, Pretlow T, et al: p53 Oncogene mutations in human prostate cancer specimens. J Urol 151:492, 1994
10. Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657, 1993
11. Bookstein R, MacGrogan D, Hilsenbeck SG, et al: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 43:3369, 1993
12. Visakorpi T, Kallioniemi O-P, Heikkinen A, et al: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883, 1992
13. Chi S-G, de Vere White RW, Meyers FJ, et al: p53 in prostate cancer: Frequent expressed transition mutations. J Natl Cancer Inst 86:926, 1994
14. Meyers FJ, Chi S-G, Fishman JR, et al: p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst 85:1856, 1993
15. Oren M, Maltzman W, Levine AJ: Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1:101, 1981
16. Baas IO, Mulder J-WR, Offerhaus GJA, et al: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5, 1994
17. Thompson SJ, Mellon K, Charlton RG, et al: p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 69:609, 1992
18. Soini Y, Pääkkö P, Nuorva K, et al: Comparative analysis of p53 protein immunoreactivity in prostatic, lung, and breast carcinomas. Virchows Arch [A] 421:223, 1992
19. Mellon K, Thompson S, Charlton RG, et al: p53, c-erbB-2 and dermal growth factor receptor in the benign and malignant prostate. J Urol 147:496, 1992
20. Van Veldhuizen PJ, Sadasivan R, Garcia F, et al: Mutant p53 expression in prostate carcinoma. Prostate 22:23, 1993
21. Fox SB, Persad RA, Royds J, et al: p53 and c-myc expression in stage Al prostatic adenocarcinoma: Useful prognostic determinants? J Urol 150:490, 1993
22. Kallakury BVS, Figge J, Ross JS, et al: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. HUM PATHOL 25:92, 1994
23. Henke R-P, Krueger E, Ayhan N, et al: Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 152:1297, 1994
24. Carroll AG, Voeller HJ, Sugars L, et al: p53 Oncogene mutations in three human prostate cancer cell lines. Prostate 23:128, 1993
25. Reiter RE, Anglard P, Liu S, et al: Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53:3092, 1993
26. Gleason DL: Histologic grading of prostatic cancer: A perspective. HUM PATHOL 23:273, 1992
27. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743, 1992
28. Taylor CR, Shi S-R, Chaiwun B, et al: Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections. HUM PATHOL 25:263, 1994
29. Cattoretti G, Pileri S, Parravicini C, et al: Antigen unmasking on formalin-fixed, paraffin-embedded tissues. J Pathol 171:83, 1993
30. Lambkin HA, Mothersill CM, Kelehan P: Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 172:13, 1994
31. Campani D, Cecchetti D, Bevilacqua G: Immunocytochemical p53 detection by microwave oven heating of routinely formalin-fixed paraffin sections. J Pathol 171:151, 1993
32. McKee PH, Hobbs C, Hall PA: Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 23:377, 1993
33. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based upon microwave oven heating of tissue sections. J Histochem Cytochem 39:741, 1991
34. Shi S-R, Cote C, Kaltra KL, et al: A technique for retrieving antigens from formalin-fixed, routinely acid decalcified, cellodiumembedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40:787, 1992
35. Norton AJ: Microwave oven heating for antigen unmasking in routinely processed tissue sections. J Pathol 171:79, 1993
36. Vojtesek B, BartekJ, Midgley CA, et al: An immunochemical analysis of human p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237, 1992
37. Teneriello MG, Ebina M, Linnoila RI, et al: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:1, 1993
38. Hayaski K, Yandell DW: How sensitive is PCR-SSCP? Hum Mutation 2:338, 1993
39. Wu JK, Ye Z, Darras BT: Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. AmJ Hum Genet 52:1273, 1993
40. Effert PJ, Neubauer A, Walther PJ, et al: Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 147:789, 1992
41. Battiforia H: p53 Immunohistochemistry: A word of caution. HUM PATHOL 25:435, 1994
42. Wynford-Thomas D: p53 In tumor pathology: Can we trust immunocytochemistry? J Pathol 166:329, 1992
43. Hall PA, Lane DP: p53 In tumour pathology: Can we trust immunohistochemistry? Revisited! J Pathol 172:1, 1994
44. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689, 1982
45. Niedobitek G, Agathanggelou A, Barber P, et al: p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 170:457, 1993
46. Shaulski G, Ben-Ze'ev, A, Rotter V: Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5:1707, 1990
47. Darzynkiewicz Z, Staiano-Coico L, Kunika JE, et al: p53 content in relation to cell growth and proliferation in murine L1210 leukemia and normal lymphocytes. Leuk Res 10:1383, 1986
48. Ryan JJ, Prochownik E, Gottlieb CA, et al: c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91:5878, 1994
49. Brown DR, Deb S, Munoz RM, et al: The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains of the MDM2 protein. Mol Cell Biol 13:6849, 1993
50. Wu X, Boyle JH, Olson DC, et al: The p53 mdm2 autoregulatory feedback loop. Genes Dev 7:1126, 1993
51. Kao CC, Yew PR, Berk AJ: Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179:806, 1990
52. Finlay CA, Hinds DW, Tan TH, et al: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531, 1988
53. Takahashi K, Sumimoto H, Suzuki K, et al: Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells. Mol Carcinogenesis 8:58, 1993
54. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262, 1992
55. Vojtesek B, Lane DP: Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 105:607, 1993